Kaku 2014.
| Methods | Randomised, double‐blind, 12‐week comparative trial, followed by a 40‐week, open‐label phase |
| Participants | 179 participants with type 2 diabetes |
| Interventions | Alogliptin and insulin versus placebo and insulin |
| Outcomes | HbA1c, body weight, hypoglycaemia |
| Notes | ‐ |